notori
low
fidel
replic
larg
respons
viru
rapid
mutat
rate
facilit
escap
immun
drug
control
errorpron
activ
viral
revers
transcriptas
rt
predict
influenti
mechan
gener
mutat
low
fidel
rt
success
exploit
nucleosid
nucleotid
analogu
revers
transcriptas
inhibitor
nrti
halt
viral
replic
upon
incorpor
consequ
drugresist
strain
arisen
viral
rt
increas
fidel
replic
thu
reduc
analogu
incorpor
higher
fidel
howev
impact
viral
fit
appear
compensatori
mutat
combin
higher
fidel
nrti
resist
mutat
subsequ
revers
nrtiresist
mutat
upon
cessat
antiretrovir
treatment
lend
support
notion
higher
fidel
exact
fit
cost
potenti
mechan
reduc
viral
fit
smaller
pool
mutant
strain
avail
respond
immun
drug
pressur
slower
rate
replic
limit
dntp
tropism
viru
unravel
relationship
replic
fidel
fit
lead
greater
understand
evolut
control
hiv
errorpron
activ
rt
pertin
sourc
sequenc
variat
review
howev
number
potenti
sourc
mutat
revers
transcript
recombin
occur
rt
transfer
two
rna
templat
present
virion
lead
insert
delet
point
transfer
well
recombin
virus
anoth
sourc
error
occur
revers
transcript
viral
genom
replic
cellular
rna
polymeras
make
error
albeit
much
lower
rate
rt
member
famili
cellular
protein
particularli
also
make
mutat
genom
furthermor
larg
popul
r
na
virus
commonli
exist
quasispeci
harbor
enorm
genet
divers
primarili
result
low
replic
fidel
divers
allow
adapt
differ
environ
pressur
immun
respons
antivir
drug
vaccin
low
replic
fidel
import
surviv
mani
rna
virus
polioviru
mutant
increas
fidel
replic
unabl
adapt
advers
growth
condit
mutant
arboviru
decreas
genet
divers
also
attenu
herein
discuss
fit
cost
aris
increas
replic
fidel
hiv
possibl
mechan
underpin
cost
remark
low
fidel
replic
result
rapid
mutat
consequ
abil
rapidli
escap
control
immun
system
antiretrovir
drug
vaccin
sequenc
genom
vari
greatli
infect
individu
within
infect
patient
low
fidel
hiv
replic
result
errorpron
natur
revers
transcriptas
rt
well
numer
potenti
sourc
variat
discuss
hiv
rt
lack
proofread
abil
cellular
polymeras
despit
share
structur
element
highfidel
polymeras
fidel
consider
lower
cellular
rna
polymeras
also
lower
retrovir
rt
hiv
rt
rel
high
affin
dntp
like
underpin
errorpron
polymer
low
fidel
hiv
rt
exploit
nucleosid
nucleotid
revers
transcriptas
inhibitor
refer
collect
nrti
analogu
natur
nucleosid
nucleotid
nrti
less
effect
host
dna
rna
polymeras
higher
fidel
resist
nrti
signific
challeng
effect
treatment
hiv
mani
differ
nrtiresist
strain
character
surpris
among
rt
higher
fidel
replic
incorpor
less
nrti
natur
nucleosid
higher
fidel
howev
come
cost
viru
main
subject
review
infect
individu
estim
hiv
virionsday
expect
exacerb
effect
famili
cellular
protein
inhibit
retrovir
pathogenesi
hypermut
ssdna
copi
block
revers
transcript
famili
member
potent
inhibit
replic
least
certain
condit
cellular
cytidin
deaminas
incorpor
hiv
virion
ultim
lead
gtoa
mutat
daughter
genom
copi
viru
absenc
vif
multipl
gtoa
mutat
crippl
viru
vif
howev
reduc
activ
promot
ubiquitin
degrad
extent
contribut
genet
variat
hiv
cours
infect
current
controversi
studi
indic
contribut
variat
subleth
level
mutagenesi
wherea
data
consist
noth
phenomenon
previous
process
revers
transcript
predict
errorpron
step
hiv
replic
cycl
howev
studi
occur
prior
character
review
focus
effect
higher
fidel
rt
mutant
viral
fit
note
activ
like
import
consequ
viral
fit
better
understood
near
futur
rt
enzym
retrovirus
uniqu
among
polymeras
use
either
rna
dna
templat
make
dna
copi
culmin
doublestrand
dna
copi
rna
genom
viru
rt
hiv
perform
two
enzymat
activ
polymer
dna
templat
degrad
rna
templat
perform
rnase
h
domain
unlik
mani
eukaryot
cellular
polymeras
hiv
rt
contain
intrins
proofread
capabl
process
hiv
revers
transcript
summar
subject
recent
comprehens
review
hiv
rt
use
genom
rna
plu
strand
cellular
trna
primer
synthes
first
strand
dna
rna
dna
duplex
thu
creat
substrat
rnase
h
domain
rt
first
strand
dna
synthes
almost
genom
rna
degrad
except
two
purinerich
sequenc
polypurin
tract
resist
rnase
h
cleavag
short
segment
rna
serv
primer
synthesi
second
dna
strand
eventu
replac
dna
copi
final
result
product
doublestrand
dna
copi
viru
rt
enzym
hiv
heterodim
two
subunit
made
gene
larger
subunit
contain
two
catalyt
domain
polymeras
rnase
h
smaller
subunit
believ
play
structur
role
rt
crystal
structur
use
determin
region
rt
directli
influenc
polymer
incom
dntp
ad
newli
synthes
dna
strand
polymeras
domain
often
compar
hand
consist
finger
palm
thumb
like
structur
fig
end
primer
posit
near
activ
site
palm
three
neg
charg
residu
interact
mg
ion
associ
incom
dntp
specif
amino
acid
residu
within
palm
finger
thumb
region
involv
process
templat
bind
primer
bind
dntp
interact
pertin
review
residu
involv
dntp
interact
directli
interact
primer
involv
templat
interact
fig
specif
mutat
residu
associ
higher
fidel
replic
tabl
low
fidel
hiv
rt
exploit
antiretrovir
therapi
use
nrti
drug
mimic
natur
nucleosid
usual
lack
group
requir
addit
next
nucleotid
drug
quit
effect
combin
therapi
drug
resist
emerg
treatment
taken
intermitt
monoor
dualtherapi
drug
resist
mediat
two
gener
mechan
remov
nrti
newli
synthes
dna
strand
pyrophosphorolysi
fig
detail
structur
wildtyp
revers
transcriptas
crosslink
dsdna
aztppppa
gener
ncbi
structur
databas
mmdb
id
use
main
diagram
show
polymeras
activ
site
detail
full
structur
insert
amino
acid
residu
describ
tabl
yellow
green
line
depict
posit
primer
orang
line
templat
upper
left
side
pink
domain
depict
finger
lower
central
pink
domain
palm
contain
activ
site
gray
domain
label
thumb
color
imag
avail
onlin
wwwliebertpubcomaid
increas
select
correct
dntp
case
significantli
chang
replic
fidel
nrti
resist
mediat
increas
select
dntp
occur
increas
rigid
rt
activ
site
decreas
affin
analogu
lead
increas
select
correct
dntp
gener
reduct
dntp
affin
result
higher
fidel
replic
mani
higher
fidel
nrtiresist
mutant
character
mechan
resist
explor
tabl
best
character
mutant
commonli
aris
treatment
zalcitabin
ddc
didanosin
ddi
lamivudin
tenofovir
tdf
estim
increas
fidel
compar
hiv
strain
mutat
report
gene
assay
tabl
also
includ
mutant
rt
rare
aris
vivo
wellcharacter
exampl
mutant
higher
fidel
term
molecular
biolog
consequ
increas
fidel
vitro
includ
reduct
amount
nrti
incorpor
polymer
reduct
incorrect
azt
lamivudin
ddi
didanosin
ddc
zalcitabin
tdf
tenofovir
ddgtp
wt
wild
type
rt
revers
transcriptas
lloyd
kent
winnal
natur
nucleotid
incorpor
gener
decreas
effici
revers
transcript
select
increas
fidel
predict
cost
fidel
viral
fit
interest
note
process
pyrophosphorolysi
remov
incorpor
nrti
may
also
impact
replic
fidel
vitro
assay
pyrophosphorolysi
abl
significantli
influenc
fidel
select
rt
consequ
pyrophosphorolysi
lesion
produc
need
repair
bypass
although
main
focu
review
note
repair
bypass
process
lesion
play
signific
role
determin
abil
hiv
rt
misincorpor
nucleotid
analyz
fidel
use
vitro
assay
overal
fidel
enzym
involv
interact
differ
factor
defin
tabl
import
misinsert
insert
incorrect
nucleotid
nucleotid
analogu
mismatch
extens
polymer
past
misinsert
number
vitro
assay
provid
specif
inform
process
three
broad
categori
vitro
assay
use
quantit
assess
rt
fidel
first
assay
determin
catalyt
constant
ie
v
max
k
effici
insert
extens
given
nucleotid
refer
kinet
assay
second
assay
use
report
gene
construct
assess
frequenc
mutat
refer
report
gene
assay
third
cellbas
assay
transfect
cell
report
gene
viru
measur
frequenc
mutat
also
note
qualit
biochem
assay
also
use
abil
rt
polymer
absenc
specif
dntp
measur
gel
electrophoresi
assay
produc
quantit
valu
mostli
supersed
one
discuss
kinet
assay
cell
free
combin
templat
primer
purifi
rt
dntp
ad
allow
polymer
two
kinet
paramet
determin
reaction
v
max
min
defin
maximum
reaction
rate
enzym
k
lm
defin
substrat
concentr
max
occur
fig
constant
use
calcul
f
in
effici
misinsert
also
refer
frequenc
misinsert
fidel
misinsert
given
nucleotid
follow
equat
equat
frequenc
misinsert
calcul
ratio
effici
insert
wrong
nucleotid
w
compar
right
nucleotid
r
effici
misinsert
use
measur
fidel
high
f
in
indic
low
fidel
insert
effici
beyond
mismatch
templateprim
quantifi
use
similar
method
effici
misinsert
effici
extens
beyond
misinsert
contribut
fidel
howev
fidel
multifactori
calcul
two
factor
alon
report
gene
assay
measur
misincorpor
polymer
entir
gene
common
report
gene
assay
forward
mutat
lacza
assay
rt
interest
combin
bacteriophag
dna
section
singlestrand
dna
length
report
gene
lacza
enzym
polymer
gap
result
product
transfect
bacteria
errorfre
synthesi
observ
dark
blue
color
coloni
light
blue
colorless
coloni
analyz
sequenc
lacza
gene
detect
mutat
howev
mutat
result
loss
lacza
protein
function
report
sinc
error
interfer
function
lacza
select
cellbas
assay
employ
report
gene
construct
way
similar
cellfre
report
gene
assay
describ
assay
cell
line
transfect
report
gene
construct
lacza
part
vector
cell
analyz
phenotyp
chang
observ
color
chang
flow
cytometri
case
fluoresc
report
assay
detect
chang
affect
report
gene
function
howev
advantag
includ
viral
host
cell
factor
interact
rt
complex
affect
function
assay
provid
import
quantit
data
fidel
specif
mutant
rt
limit
techniqu
assay
employ
templat
reflect
hiv
genom
kinet
cellfre
report
gene
assay
use
purifi
rt
viral
host
cell
factor
part
vivo
rt
complex
absent
perhap
reflect
studi
show
purifi
rt
higher
mutat
rate
whole
viru
vivo
rang
method
reagent
primer
templat
report
gene
assay
vari
wide
may
explain
variat
fidel
data
given
mutant
describ
tabl
despit
variat
assay
encourag
consensu
experi
use
assay
suggest
rt
mutant
describ
tabl
higher
fidel
wildtyp
unmut
rt
capac
viru
produc
infecti
progeni
replic
comparison
anoth
strain
viru
term
fit
viru
mutat
reduc
rel
replic
capac
viru
refer
fit
cost
fit
cost
measur
number
increasingli
sophist
way
simpl
level
replic
kinet
hiv
variant
cell
line
compar
although
rel
insensit
subtl
fit
cost
competit
assay
two
virus
seed
tissu
cultur
period
time
win
viral
strain
detect
end
cultur
fairli
sensit
assay
particularli
perform
primari
blood
cell
rather
cell
line
effect
expens
method
assess
fit
observ
revers
particular
mutat
vivo
macaqu
infect
experi
siv
chimer
shiv
virus
experi
accur
reflect
total
fit
impact
given
mutat
one
final
vivo
method
use
test
fit
cost
drugresist
mutant
involv
monitor
decay
drugresist
viru
patient
stop
treatment
specif
antiretrovir
main
advantag
studi
translat
readili
clinic
situat
involv
human
howev
drugresist
mutant
test
fashion
wherea
compensatori
mutat
also
need
taken
account
evid
alter
fidel
rt
either
increas
decreas
nucleotid
select
detriment
viral
fit
becom
increasingli
clear
increas
fidel
alway
come
fit
cost
higher
fidel
mutant
replic
slowli
cell
line
vivo
studi
human
sivinfect
macaqu
show
mutant
less
fit
wildtyp
virus
often
revert
wildtyp
absenc
drug
treatment
vivo
fit
cost
particularli
interest
mutat
appear
earli
transient
treatment
replac
mutant
mutant
higher
fidel
tabl
data
indic
greater
fit
cost
compar
lower
fidel
comprehens
comparison
fit
cost
associ
chang
hiv
fidel
found
signific
posit
correl
fidel
fit
cost
highfidel
hiv
mutant
interestingli
show
low
fidel
also
associ
lower
viral
fit
compensatori
mutat
addit
chang
viral
genom
predict
offset
fit
cost
initi
mutat
often
aris
presenc
select
pressur
immun
respons
drug
treatment
associ
presenc
known
drug
escap
mutant
compensatori
mutat
confer
resist
restor
partial
replic
fit
exampl
mutat
increas
fit
mutant
rt
mani
higher
fidel
mutant
associ
compensatori
mutat
support
predict
increas
fidel
come
cost
like
level
replic
fidel
achiev
optim
fit
actual
balanc
wherebi
high
fidel
well
low
fidel
decreas
fit
predict
mutat
rate
rna
virus
hiv
sit
near
critic
error
threshold
consid
near
theoret
extinct
threshold
effect
lower
fidel
predict
make
genom
unstabl
produc
mani
nonviabl
hiv
genom
certainli
evid
mani
mutat
decreas
fit
quasispeci
demonstr
studi
aforement
absenc
vif
hiv
could
suppress
activ
underw
hypermut
crippl
viru
dapp
et
al
demonstr
neg
correl
mutat
frequenc
viral
fit
lowfidel
mutant
hiv
strain
even
rel
small
increas
mutat
rate
decreas
fit
evid
come
mutat
high
fidel
compar
rt
mutant
tabl
rt
carri
lower
incorpor
incorrect
endogen
nucleotid
lacza
report
gene
assay
like
due
decreas
abil
extend
past
mismatch
kinet
assay
creat
mutagenesi
studi
base
nrtiresist
mutat
small
increas
fidel
version
also
drug
resist
rare
aris
patient
perhap
indic
high
fidel
unten
studi
fit
higher
fidel
mutant
togeth
assay
describ
chang
rt
fidel
outlin
provid
insight
mechan
behind
fit
cost
higher
fidel
discuss
three
potenti
mechan
decreas
fit
higher
fidel
smaller
pool
mutat
avail
facilit
escap
immun
drug
control
reduc
process
andor
rate
replic
lower
affin
dntp
may
limit
tropism
viru
reduc
pool
mutat
avail
facilit
escap
immun
respons
drug
treatment
lloyd
kent
winnal
logic
outcom
increas
fidel
replic
although
demonstr
occur
vivo
current
lack
larg
pool
mutat
would
certainli
advantag
presenc
drug
healthi
immun
system
make
vaccin
hiv
difficult
mani
studi
track
escap
hiv
infect
immun
pressur
neutral
antibodi
ctl
respons
antibodydepend
cellular
cytotox
show
specif
mutat
commonli
associ
escap
immun
pressur
similarli
plethora
drugresist
mutat
consist
aris
treatment
logic
predict
viru
produc
smaller
pool
mutat
due
higher
fidel
reduc
capac
overcom
pressur
highfidel
mutant
may
reduc
fit
host
deplet
immun
system
support
point
discoveri
natur
occur
higher
fidel
rt
mutant
conserv
region
simian
immunodefici
viru
mutat
aros
absenc
drug
treatment
late
stage
infect
immun
pressur
diminish
due
cell
deplet
clonal
exhaust
possibl
condit
higher
fidel
replic
may
reduc
number
nonviabl
mutant
virus
produc
second
potenti
mechan
underpin
reduc
fit
higher
fidel
rt
mutant
reduct
rate
replic
andor
process
rt
rt
mutant
select
correct
dntp
like
polymer
dna
slowli
numer
studi
determin
lower
v
max
k
tabl
mani
higher
fidel
rt
support
predict
furthermor
mani
higher
fidel
mutant
rt
shown
lower
process
defin
length
time
enzym
remain
associ
nucleic
acid
process
howev
direct
measur
rate
replic
strand
transfer
occur
rt
dissoci
continu
polymer
understand
relationship
fidel
process
evolv
although
evid
neg
relationship
process
fidel
mutant
similar
studi
rt
harbor
found
relationship
furthermor
emerg
evid
suggest
appar
process
defect
may
due
alter
dntp
affin
mutant
final
reduct
dntp
affin
higher
fidel
mutant
propos
limit
tropism
hiv
therebi
reduc
fit
hiv
vivo
increas
select
high
fidel
mutant
often
modul
activ
site
chang
lead
decreas
dntp
affin
consequ
analyz
context
polymer
kinet
viru
tropism
cellbas
assay
shown
mutant
sever
reduc
growth
primari
cell
low
dntp
concentr
mutant
also
lower
affin
dntp
abil
infect
cell
lower
dntp
concentr
remain
poorli
character
sinc
target
cell
macrophag
contain
low
dntp
level
lower
dntp
affin
predict
limit
viral
tropism
vivo
therebi
reduc
fit
viru
manner
lower
dntp
affin
associ
higher
fidel
may
specif
select
disadvantag
addit
gener
impact
rate
replic
next
gener
fidel
analysi
highthroughput
sequenc
assay
measur
biochem
properti
rt
cellbas
lacza
assay
quantifi
mutat
rate
provid
import
mechanist
inform
measur
analyz
total
misincorpor
hiv
replic
vivo
would
greatli
contribut
understand
relationship
fidel
fit
prior
emerg
highthroughput
nextgener
sequenc
technolog
direct
detect
viral
genom
mutat
involv
clone
sequenc
individu
genom
process
time
consum
expens
yield
limit
data
small
proport
genotyp
present
plasma
patient
exampl
would
analyz
highthroughput
sequenc
provid
mean
take
snapshot
entir
viral
popul
given
time
sequenc
platform
illumina
solid
ion
torrent
gener
million
sequenc
read
per
run
provid
depth
necessari
theoret
analyz
hiv
genom
present
patient
sampl
techniqu
current
revolution
studi
hiv
sequenc
divers
applic
rang
drug
resist
monitor
explor
total
antibodi
respons
yet
appli
question
viral
fidel
publish
studi
technic
challeng
need
overcom
accur
measur
replic
fidel
differ
hiv
strain
vivo
higher
fidel
mutant
less
fit
like
produc
fewer
viral
particl
wildtyp
viru
consequ
may
produc
fewer
mutat
result
decreas
replic
rather
increas
fidel
similarli
fit
cost
increas
likelihood
revers
especi
vivo
mix
popul
wt
rt
fidel
mutant
would
complic
fidel
measur
nevertheless
highthroughput
sequenc
enorm
potenti
promis
much
greater
explor
genom
popul
higher
fidel
mutant
key
increas
understand
cost
fidel
live
attenu
vaccin
proven
effect
prevent
mani
viral
diseas
smallpox
polio
measl
earli
vaccin
strain
deriv
empir
passag
cell
line
howev
ration
attenu
virus
common
approach
rna
virus
harbor
extens
genet
divers
particularli
challeng
candid
like
escap
attenu
mutat
lowfrequ
mutant
may
escap
vaccineelicit
immun
respons
attenu
rna
virus
increas
replic
fidel
one
possibl
strategi
design
liveattenu
virus
one
exampl
polioviru
variant
increas
replic
fidel
liveattenu
vaccin
success
protect
mice
lethal
dose
polioviru
interest
altern
highfidel
liveattenu
vaccin
design
sever
acut
respiratori
syndrom
sar
coronaviru
vaccin
candid
reduc
fidel
replic
suffici
attenu
viru
afford
protect
mous
model
possibl
mutant
hiv
strain
increas
replic
fidel
could
make
effect
liveattenu
vaccin
howev
use
liveattenu
hiv
vaccin
human
seem
unlik
becom
realiti
due
safeti
efficaci
concern
regardless
studi
liveattenu
siv
vaccin
macaqu
provid
use
inform
type
immun
respons
necessari
prevent
siv
infect
make
import
contribut
understand
effect
vaccineinduc
immun
hiv
higher
fidel
replic
predict
come
cost
fit
viru
overal
level
hiv
rt
fidel
like
balanc
high
fidel
lead
reduct
viral
fit
low
fidel
also
detriment
propag
viru
manipul
viral
fidel
therefor
possibl
rout
control
viru
understand
relationship
fidel
viral
fit
lead
better
appreci
hiv
evolut
potenti
control
viru
certainli
enhanc
applic
highthroughput
sequenc
studi
fidel
replic
vivo
